trending Market Intelligence /marketintelligence/en/news-insights/trending/lmjs4ucc_ahlycg3cgeg9g2 content esgSubNav
In This List

Breathtec Biomedical to undergo 2-for-1 consolidation amid NASH acquisition

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


Breathtec Biomedical to undergo 2-for-1 consolidation amid NASH acquisition

Breathtec Biomedical Inc. will undergo a 2-for-1 consolidation of its common shares pursuant to its acquisition agreement with NASH Pharmaceuticals Inc.

The Vancouver, British Columbia-based company, which is registered with the Canadian Securities Exchange, will begin trading on a post-consolidated basis from Oct. 17, according to a press release.

Breathtec Biomedical's issued and outstanding common shares will reduce from 57,897,356 to 28,948,678.

The company develops breath-analysis technology for the early screening of life-threatening diseases.